Targeted drug treatment of tumors has significant market potential
2018-05-10 17:00:26
Recently, the first China CSCO Targeted Therapy Knowledge Competition held by AstraZeneca officially kicked off in three competition areas in Shanghai, Beijing and Guangzhou. According to AstraZeneca, the purpose of the competition was to target cancer treatment. The advanced treatment methods are more widely and correctly applied to the clinical treatment of tumors, so as to improve the curative effect and improve the patient's quality of life through multidisciplinary and multi-pathway treatments.
It is understood that the incidence of cancer is increasing, and lung cancer is currently one of the highest cancer death rates in the world. In recent years, the incidence of lung cancer in China, especially non-small cell lung cancer, has been increasing year by year. At the same time, as the most commonly used method for the treatment of advanced non-small cell lung cancer, the efficacy of chemotherapy has entered a bottleneck stage.
According to Professor Lin Tongyin, Associate Dean of Cancer Hospital of Sun Yat-sen University, clinical experience has shown that the efficiency of chemotherapy for non-small cell lung cancer treatment is generally around 30% to 40%. How to further improve the efficacy, improve the quality of life of patients, and prolong the survival of patients Time is of concern. Targeted tumor therapy is a hot spot in the 21st century for cancer treatment. Its advantage is that it uses cancer cells as specific targets and can accurately act on tumors. Therefore, it does not or rarely damage normal cells, resulting in relatively small adverse reactions. It has been proved to play a significant role in the treatment of various tumors including non-small cell lung cancer, lymphoma, head and neck cancer, breast cancer, and colorectal cancer.
It is understood that the incidence of cancer is increasing, and lung cancer is currently one of the highest cancer death rates in the world. In recent years, the incidence of lung cancer in China, especially non-small cell lung cancer, has been increasing year by year. At the same time, as the most commonly used method for the treatment of advanced non-small cell lung cancer, the efficacy of chemotherapy has entered a bottleneck stage.
According to Professor Lin Tongyin, Associate Dean of Cancer Hospital of Sun Yat-sen University, clinical experience has shown that the efficiency of chemotherapy for non-small cell lung cancer treatment is generally around 30% to 40%. How to further improve the efficacy, improve the quality of life of patients, and prolong the survival of patients Time is of concern. Targeted tumor therapy is a hot spot in the 21st century for cancer treatment. Its advantage is that it uses cancer cells as specific targets and can accurately act on tumors. Therefore, it does not or rarely damage normal cells, resulting in relatively small adverse reactions. It has been proved to play a significant role in the treatment of various tumors including non-small cell lung cancer, lymphoma, head and neck cancer, breast cancer, and colorectal cancer.